Showing results (101-110 of 114) with videos related to

Sort By:
Pageof 12
Annals of Medicine|October 11, 2025
Disitamab vedotin plus programmed death-1 inhibitor for pre-treated HER2 overexpressed advanced gastric cancer: a multicentre retrospective real-world studyXiao Yan, Zhong Xie, Kaobin Ouyang, et al.
Nano Letters|December 2, 2024
Moiré Exciton Polaron Engineering via twisted hBNMinhyun Cho, Biswajit Datta, Kwanghee Han, et al.
Mabs|August 4, 2021
Targeting and pharmacology of an anti-IL13Rα2 antibody and antibody-drug conjugate in a melanoma xenograft modelParul Gupta, Ziyue Karen Jiang, Bing Yang, et al.
International Journal of Surgery (London, England)|September 18, 2023
Clinical outcomes of conversion surgery following immune checkpoint inhibitors and chemotherapy in stage IV gastric cancerHuayuan Liang, Xiao Yan, Zhiwei Li, et al.
Theranostics|July 21, 2020
Nuclear MYH9-induced CTNNB1 transcription, targeted by staurosporin, promotes gastric cancer cell anoikis resistance and metastasisGengtai Ye, Qingbin Yang, Xuetao Lei, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|June 16, 2023
N4-Acetylcytidine Drives Glycolysis Addiction in Gastric Cancer via NAT10/SEPT9/HIF-1α Positive Feedback LoopQingbin Yang, Xuetao Lei, Jiayong He, et al.
Eclinicalmedicine|August 21, 2025
Efficacy and safety of neoadjuvant toripalimab plus chemotherapy in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma (NICE): a multicentre, single-arm, exploratory phase 2 studyLiying Zhao, Hao Liu, Jiang Yu, et al.
Nature Communications|April 23, 2026
Neoadjuvant toripalimab plus CapeOX in locally advanced Epstein-Barr virus-associated gastric or gastroesophageal junction adenocarcinoma: a phase Ⅱ trialLiying Zhao, Hao Liu, Yanfeng Hu, et al.
Cancer Cell International|January 4, 2018
Establishment and evaluation of four different types of patient-derived xenograft modelsXiaoqian Ji, Siyu Chen, Yanwu Guo, et al.
The AAPS Journal|April 26, 2017
Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug ConjugatesL Nathan Tumey, Fengping Li, Brian Rago, et al.
Pageof 12